Gilead beats product hopping claims ahead of trial
A California federal court has thrown out product-hopping claims against Gilead Sciences relating to one of its HIV treatments, although the drugmaker and several others failed to escape allegations they agreed anticompetitive non-competes and pay-for-delay schemes.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10